A pre-emptive approach to treating leukaemia relapse

The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is helping patients live longer with acute myeloid leukaemia (AML).

Related Keywords

Melbourne ,Victoria ,Australia ,Nemes Laszlo ,Peter Mac ,Andrew Wei ,Lymphoma Group ,Peter Maccallum Cancer Centre Mac ,Peter Maccallum Cancer Centre ,Ing Soo Tiong ,Clinical Oncology ,Royal Melbourne Hospital ,Australasian Leukaemia ,Leukaemia ,Relapse ,Measurable Residual Disease ,Yard ,Chemotherapy ,Acute Myeloid Leukaemia ,Pml ,Journal Of Clinical Oncology ,